June 2017 Br J Cardiol 2017;24:61
BJCardio Staff
Nanoparticles, inhaled from sources such as vehicle exhausts, have been shown to cross from the lungs into the blood stream. They can then accumulate in areas susceptible to heart problems, according to research part-funded by the British Heart Foundation. Previous studies have identified a correlation but not a causal link between nanoparticles and strokes or cardiovascular disease. It is not currently possible to measure environmental nanoparticles in the blood. So, researchers from the University of Edinburgh, and the National Institute for Public Health and the Environment in the Netherlands, used a variety of specialist techniques to t
December 2015 Br J Cardiol 2016;23:(1) Online First
BJCardio Staff
News from ERS High levels of anxiety and depression in PH Psychological morbidity remains under-diagnosed in pulmonary hypertension (PH), and one third of patients suffer from depression and/or anxiety for which only 38% are being treated, according to a study conducted by Dr Gina Somaini and colleagues (University Hospital of Zurich, Switzerland). They investigated the prevalence and course of anxiety and depression and their association with health-related quality of life (HRQoL) disease markers and survival over a mean period of 16 months. In the study, 45 newly diagnosed and 86 pretreated patients with arterial and chronic thromboembolic
August 2015 Br J Cardiol 2015;22:92–3
BJCardio Staff
PCSK9 approvals in Europe Two agents in a new cholesterol-lowering class – the PCSK9 inhibitors, which use human monoclonal antibodies to target PCSK9 (proprotein convertase subtilisin/kexin type 9) – have received European approval for lowering cholesterol. Evolocumab (Repatha®, Amgen) is the first PCSK9 inhibitor to be granted marketing authorisation by the European Commission (EC) for use in people with primary hypercholesterolaemia or mixed dyslipidaemia, or in homozygous familial hypercholesterolaemia, who are unable to reach low-density lipoprotein cholesterol (LDL-C) goals with an optimal dose of statin (or a statin and other lipi
July 2010 Br J Cardiol 2010;17:175-9
Alison Child, Jane Sanders, Paul Sigel, Myra S Hunter
(more…)
May 2006 Br J Cardiol 2006;13:220-4
Everard W Thornton, Peter Bundred, Michelle Tytherleigh, Ann DM Davies
No content available
September 2005 Br J Cardiol 2005;12:361-6
Allison Thorpe, Sian Griffiths, Charles F George
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits